Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia

Velier, Mélanie; Priet, Stéphane; Appay, Romain; Atieh, Thérèse; Lépidi, Hubert; Kaplanski, Gilles; Jarrot, Pierre André; Koubi, Marie; Costello, Régis; Dignat-George, Françoise; Lamballerie, Xavier de; Tichadou, Antoine; Arcani, Robin; Couderc, Anne-Laure; Touati, Julian; Varoquaux, A.; Berda-Haddad, Yaël; Venton, Geoffroy

doi:10.1016/j.clml.2021.01.005

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Yasuda et al, found that patients who underwent recent rituximab therapy were less likely to develop anti-SARS-CoV-2 antibodies thereby, becoming more likely to experience severe and prolonged COVID-19 infections, as well as bacterial or fungal pneumonia. 13,[31][32][33][34][35][36] Conversely, recently some groups have reported rare cases of anti-tumor response in lymphoma patients after COVID-19 infection. [37][38][39][40][41] This interesting finding has been observed in subtypes ranging from natural killer (NK), HL, follicular lymphoma (FL), and the hypothesis around the mechanisms responsible for the anti-tumor response, warrants further investigation across lymphoma subtypes.…”

Section: Literature Review Methodologymentioning

confidence: 99%

“…Due to the nature of lymphoma, or B‐cell targeting treatments, lymphopenia or immunosuppression, are often seen. A study by Yasuda et al, found that patients who underwent recent rituximab therapy were less likely to develop anti‐SARS‐CoV‐2 antibodies thereby, becoming more likely to experience severe and prolonged COVID‐19 infections, as well as bacterial or fungal pneumonia 13,31–36 . Conversely, recently some groups have reported rare cases of anti‐tumor response in lymphoma patients after COVID‐19 infection 37–41 .…”

Section: Pathophysiological Effects Of Covid‐19 In Lymphoma Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic

Elliott

Hensen

Haupt

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

The Coronavirus disease 2019 (COVID-19) pandemic has dramatically impacted the health risk and management of patients with lymphoma. Clinical evaluations on the impact of COVID-19 on lymphoma patients are currently limited however, reports have shown a correlation with specific variants and more severe COVID-19 complications and higher mortality rates relative to other disease states and age-matched populations. During peak pandemic periods this created a concerning management problem for clinicians and raised the question of how different immunocompromised states increase COVID-19-associated risk and provided

show abstract

Section: Literature Review Methodologymentioning

confidence: 99%

Section: Pathophysiological Effects Of Covid‐19 In Lymphoma Patientsmentioning

confidence: 99%

Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic

Elliott

Hensen

Haupt

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

show abstract

Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell Lymphoma

et al. 2022

View full text Add to dashboard Cite

Patient: Male, 80-year-old Final Diagnosis: COVID 19 infection • primary bone marrow diffuse large B cell lymphoma Symptoms: Fatigue • fever • weight loss Medication: — Clinical Procedure: Bone marrow biopsy Specialty: Hematology • Infectious Diseases • Oncology Objective: Rare disease Background: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). While bone marrow (BM) involvement is common in lymphoma, primary bone marrow (PBM) DLBCL is extremely rare. We present a case of PBM DLBCL discovered in a patient with COVID-19. Case Report: An 80-year-old man presented with generalized abdominal pain, weight loss, fever, fatigue, anorexia, and watery diarrhea over a 3-month period. Physical examination was unremarkable. Laboratory workup revealed anemia, thrombocytopenia, and elevated inflammation markers. SARS-COV-2 PCR was positive, while blood cultures were negative. A rapid decline in the white blood cell count in the following days prompted a BM biopsy, confirming the diagnosis of PBM DLBCL. Computed tomography (CT) did not show thoracic or abdominal lymphadenopathy. The patient received packed red blood cell and platelet transfusions, granulocyte colony-stimulating factor (G-CSF) for pancytopenia, and empirical antibiotics for suspected infection. Due to active COVID-19 and advanced age, cytotoxic chemotherapy was delayed. Rituximab and prednisone were initiated on day 9, followed by an infusion reaction, which led to treatment discontinuation. He died 2 days later. Conclusions: Diagnosing PBM malignancy is challenging, especially with coexisting infection. It is essential to suspect underlying BM malignancy in patients with clinical deterioration and worsening pancytopenia despite adequate treatment. The diagnosis of PBM DLBCL requires the absence of lymphadenopathy, and the presence of histo-logically confirmed DLBCL. Prompt management with combination chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with/without hematopoietic stem cell transplant can improve the prognosis.

show abstract

COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review

Bonuomo¹,

Ferrarini²,

Dell'Eva³

et al. 2021

WJV

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection now has a global resonance and represents a major threat for several patient populations. Observations from initial case series suggested that cancer patients in general might have an unfavorable outcome following coronavirus disease 2019 (COVID-19), due to their underlying conditions and cytotoxic treatments. More recently, data regarding the incidence and clinical evolution of COVID-19 in lymphomas have been reported with the aim to identify those more frequently associated with severe complications and death. Patients with lymphoma appear particularly vulnerable to SARS-CoV-2 infection, only partly because of the detrimental effects of the anti-neoplastic regimens (chemotherapy, pathway inhibitors, monoclonal antibodies) on the immune system. Here, we systematically reviewed the current literature on COVID-19 in adult patients with lymphoma, with particular emphasis on disease course and prognostic factors. We also highlighted the potential differences in COVID-19 clinical picture according to lymphoma subtype, delivered treatment for the hematological disease and its relationship on how these patients have been managed thus far.

show abstract

Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia

Cited by 3 publications

References 11 publications

Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic

Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic

Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell Lymphoma

COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review

Contact Info

Product

Resources

About